Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 10/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.52 |
| ▸ | USP2 | O75604 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 9/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30162860 | 1.00 | GBA1 (0.55) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21996554 | 0.89 | GBA1 (0.70) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29840025 | 0.89 | GBA1 (0.70) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23459690 | 0.88 | GBA1 (0.53) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21996558 | 0.87 | GBA1 (0.58) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30162953 | 0.87 | GBA1 (0.58) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21996597 | 0.87 | GBA1 (0.58) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30162649 | 0.87 | GBA1 (0.58) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30867198 | 0.80 | GBA1 (0.49) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27319878 | 0.80 | GBA1 (0.49) | GBA1KMT2ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028680-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | CELULARITY INC. (US) | 2023-01-26 | — | — | US | claimed |
| US-20220251104-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | CELULARITY INC. (US) | 2022-08-11 | — | — | US | claimed |
| EP-3887364-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | Celularity Inc. (US) | 2021-10-06 | — | — | EP | claimed |
| EP-3887508-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | Celularity Inc. (US) | 2021-10-06 | — | — | EP | claimed |
| WO-2020113178-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | claimed |
| WO-2020113182-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | claimed |
| US-20250295776-A1 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | CELULARITY INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250276063-A1 | PLACENTA-DERVIED NK CELLS AS A SENOL YTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023010123-A1 | PLACENTA-DERVIED NK CELLS AS A SENOLYTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010123-A1 | PLACENTA-DERVIED NK CELLS AS A SENOLYTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230028680-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | CELULARITY INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021113849-A1 | HER2+ CANCER TREATMENT WITH POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021022229-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021022229-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020252464-A1 | POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS | CELULARITY INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252464-A1 | POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS | CELULARITY INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020113182-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020113178-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | Celularity, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295776-A1 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | PBK, PIGK, CD74 | GBA1 2518/4885KMT2A 2405/4885CYP1A2 4844/4885 |
| US-20230355759-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | PBK, KLKB1, PIGK | GBA1 962/4885KMT2A 1363/4885CYP1A2 3067/4885 |
| US-20230028680-A1 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | PBK, ILF3, NFATC1 | GBA1 4011/4885KMT2A 2012/4885CYP1A2 1816/4885 |
| US-20220251104-A1 | AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS | ALPP, MCL1, NFATC1 | GBA1 4613/4885KMT2A 449/4885CYP1A2 1005/4885 |
| US-20250276063-A1 | PLACENTA-DERVIED NK CELLS AS A SENOL YTIC FOR THERAPEUTIC AND OTHER USES | PBK, CD47, GZMB | GBA1 1032/4885KMT2A 1380/4885CYP1A2 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.